Please find attached letter regarding Increase in Authorised Share Capital of the Company

Date: 03/09/2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 514330/Scrip ID: ONEGLOBAL Subject: Outcome of Board Meeting held on Thursday, 3rd September, 2026 Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) Dear Sir/Madam, Pursuant to Regulation 30, and other applicable provisions of SEBI LODR Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., Thursday, 3rd September, 2026, have inter-alia, considered and approved the following(s): 1. Appointment of M/s. S D P M & Co; (FRN:126741W) Chartered Accountants, as the Statutory Auditors of the Company: Based on the recommendation of the Audit Committee, the Board of Directors of the Company recommended appointment of M/s. S D P M (FRN:126741W) Chartered Accountants, as the Statutory Auditors of the Company to hold the office for a second term of 5 (five) consecutive years from the conclusion of 34th Annual General Meeting (“AGM”) of the Company till the conclusion of the 39th AGM, subject to the approval of the Members of the Company and other statutory requirements. Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), is enclosed as ‘Annexure A’. 2. Appointment of M/s. Valawat & Associates, (FRN: 434660) Chartered Accountants, as the Internal Auditors of the Company: Based on the recommendation of the Audit Committee, the Board of Directors of the Company recommended appointment of M/s. Valawat & Associates, (FRN: 434660) Chartered Accountants, as the Internal Auditors of the Company for the Financial Year 2026-27. Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), is enclosed as ‘Annexure B’. 3. Approval for Acquisition 51% Equity Stake in Matrix Labs Diagnocare Private Limited and Matrix Labs Private Limited, respectively and Issuance of Equity Shares on Preferential Basis: The Board of Directors of the Company, has approved, subject to the approval of the Members of the Company and such other statutory and regulatory approvals as may be required, the acquisition of 51% equity stake in each of Matrix Labs Diagnocare Private Limited (“MLDPL”) and Matrix Labs Private Limited (“MLPL”). In this regard, the Company proposes to acquire 13,321 equity shares of MLDPL and 2,550 equity shares of MLPL, representing 51% of the total issued, subscribed and paid-up equity share capital of MLDPL and MLPL, respectively. ONE GLOBAL SERVICE PROVIDER LIMITED (Formerly known as Overseas Synthetics Limited) CIN : L74110MH1992PLC367633 Telephone : 8657527323 Website : www.1gsp.in E-mail : 1connect@1gsp.in Registered Address : 6th Floor, 601 E Wing, Trade Link Building, B & C Block, Senapati Bapat Marg, Kamla Mill Compound, Lower Parel (W) Mumbai 400013 The aforesaid equity shares are proposed to be acquired from Mr. Suresh and Ms. Nithya S in the case of MLDPL and from Mr. Suresh in the case of MLPL, for a non - cash consideration of Rs. 35,97,81,800/- (Rupees Thirty-Five Crore Ninety-Seven Lakh Eighty-One Thousand Eight Hundred Only) and Rs. 3,56,35,320/- (Rupees Three Crore Fifty-Six Lakh Thirty-Five Thousand Three Hundred Twenty Only), respectively. The consideration for the proposed acquisition shall be discharged by way of issuance and allotment of equity shares of the Company on a preferential basis, in consideration other than cash, pursuant to a share swap arrangement. Accordingly, the Company proposes to issue, offer and allot 6,01,760 (Six Lakh One Thousand Seven Hundred Sixty Only) and 48,480 (Forty Thousand Forty Eighty), equity shares of the Company to Mr. Suresh and Ms. Nithya S, respectively, against the acquisition of 51% equity stake in MLDPL and 64,440 (Sixty-Four Thousand Four Hundred Forty Only) equity shares of the Company to Mr. Suresh against the acquisition of 51% equity stake in MLPL. The equity shares proposed to be issued shall have a face value of Rs. 10/- each and shall be issued at a price of Rs. 553/- (Rupees Five Hundred Fifty-Three Only) per equity share, including premium aggregating to Rs. 39,54,17,120/-(Rupees Thirty-Nine Crore Fifty-Four Lakh Seventeen Thousand One Hundred Twenty Only), which shall not be less than the price determined in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”). The disclosures required pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time or any master circular in force as on the date of filing, are enclosed herewith as ‘Annexure C1 & C2’ respectively. 4. Execution of Share Purchase Agreements for Acquisition of 51% Equity Stake: In furtherance of the aforesaid acquisition, the Company has entered into the following Share Purchase Agreements (“SPAs”) dated 3rd September, 2026 a) Matrix Labs Diagnocare Private Limited (“MLDPL”): An SPA has been entered into between One Global Service Provider Limited, Mr. Suresh, Ms. Nithya S and Matrix Labs Diagnocare Private Limited for the acquisition by the Company of 13,321 equity shares of MLDPL, representing 51% of the total issued, subscribed and paid-up equity share capital of MLDPL. b) Matrix Labs Private Limited (“MLPL”): An SPA has been entered into between One Global Service Provider Limited, Mr. Suresh and Matrix Labs Private Limited for the acquisition by the Company of 2,550 equity shares of MLPL, representing 51% of the total issued, subscribed and paid-up equity share capital of MLPL. Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), are enclosed herewith as ‘Annexure D1 and D2’ respectively. 5. Preferential Issue of Equity Shares for Consideration Other than Cash: The Company proposes to issue, offer and allot 7,15,040 (Seven Lakh Fifteen Thousand Forty Only) fully paid-up equity shares of the Company on a preferential basis, having a face value of Rs. 10/- each, at an issue price of Rs. 553/- (Five Hundred Fifty-Three Only) per equity share, including premium (“Allotment Shares”), to Mr. Suresh and Ms. Nithya S, towards discharge of the non- cash consideration payable by the Company for the acquisition of 13,321 (Thirteen Thousand Three Hundred Twenty-One Only) equity shares of Matrix Labs Diagnocare Private Limited (“MLDPL”), representing 51% of its total issued, subscribed and paid-up equity share capital, and to Mr. Suresh, ONE GLOBAL SERVICE PROVIDER LIMITED (Formerly known as Overseas Synthetics Limited) CIN : L74110MH1992PLC367633 Telephone : 8657527323 Website : www.1gsp.in E-mail : 1connect@1gsp.in Registered Address : 6th Floor, 601 E Wing, Trade Link Building, B & C Block, Senapati Bapat Marg, Kamla Mill Compound, Lower Parel (W) Mumbai 400013 towards discharge of the non-cash consideration payable by the Company for the acquisition of 2,550 (Two Thousand Five Hundred Fifty Only) equity shares of Matrix Labs Private Limited (“MLPL”), representing 51% of its total issued, subscribed and paid-up equity share capital (collectively, the “Purchase Shares”). Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, [Showing first 8,000 characters — download PDF for full document]